ADReCS

Pharmaceutical Information

Drug Name	Hydroxyurea
Drug ID	BADD_D01110
Description	An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
Indications and Usage	For management of melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary and Sickle-cell anemia.
Marketing Status	approved
ATC Code	L01XX05
DrugBank ID	DB01005
KEGG ID	D00341
MeSH ID	D006918
PubChem ID	3657
TTD Drug ID	D07CWD
NDC Product Code	0904-6939; 35369-0006; 49452-3650; 55154-7143; 61269-403; 68084-284; 70518-3615; 51927-0072; 0555-0882; 55154-3554; 69315-164; 38779-1354; 42291-321; 71770-105; 49884-724; 17337-0023; 0003-6335; 0003-6337; 60429-265; 61269-835; 70518-0916; 55512-0003; 61269-402; 71770-120; 0003-0830; 51552-0851; 62049-135; 0003-6336; 61269-404; 10135-702; 71052-323; 17337-0022
UNII	X6Q56QN5QC
Synonyms	Hydroxyurea \| Hydroxycarbamid \| Oncocarbide \| Hydrea

Chemical Information

Molecular Formula	CH4N2O2
CAS Registry Number	127-07-1
SMILES	C(=O)(N)NO
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Febrile neutropenia	08.05.02.004; 01.02.03.002	0.000392%
Feeling abnormal	08.01.09.014	-	-	Not Available
Fibrosis	08.03.01.001	0.000112%		Not Available
Fluid retention	20.01.02.003; 14.05.06.002	0.000168%		Not Available
Folate deficiency	14.12.02.006	-	-	Not Available
Gangrene	24.04.05.003; 23.06.06.001; 11.02.01.003	-	-	Not Available
Gastric cancer	16.13.03.001; 07.21.02.001	0.000728%		Not Available
Gastric haemorrhage	24.07.02.007; 07.12.01.001	0.000224%
Gastric ulcer	07.04.03.002	0.000336%
Gastrointestinal disorder	07.11.01.001	-	-	Not Available
Gastrointestinal haemorrhage	24.07.02.009; 07.12.02.001	0.000504%		Not Available
Generalised tonic-clonic seizure	17.12.01.002	0.000112%		Not Available
Gout	15.01.06.001; 14.09.01.001	0.000112%		Not Available
Haematemesis	24.07.02.011; 07.12.02.002	0.000224%		Not Available
Haematochezia	24.07.02.012; 07.12.02.003	0.000168%		Not Available
Haematoma	24.07.01.001	0.000336%
Haematuria	20.02.01.006; 21.10.01.018; 24.07.01.047	0.000224%
Haemoglobin	13.01.05.018	-	-	Not Available
Haemolysis	01.06.04.002	0.000112%
Haemolytic anaemia	01.06.03.002	0.000336%		Not Available
Hallucination	19.10.04.003	-	-
Headache	17.14.01.001	-	-
Hemiparesis	17.01.04.001	0.000168%
Hemiplegia	17.01.04.002	0.000224%		Not Available
Hepatic failure	09.01.03.002	0.000112%
Hepatic function abnormal	09.01.02.001	0.001030%		Not Available
Hepatitis	09.01.07.004	0.000168%		Not Available
Hepatocellular injury	09.01.07.008	0.000112%		Not Available
Hepatosplenomegaly	09.01.05.002; 01.09.03.001	0.000168%		Not Available
Hepatotoxicity	12.03.01.008; 09.01.07.009	0.000112%		Not Available

The 4th Page First Pre 4 5 6 7 8 Next Last Total 13 Pages